Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels.
Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.
PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.
Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.
Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases. Companies operating in this pipeline space include Gmax Biopharm, Actelion Pharmaceuticals and Theravance Biopharma.
This report “Blood Pressure Disorders Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.
- Which companies are the most active within the pipeline for blood pressure disorders?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons To Buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration